Nadine Kutsch

15PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 17, 2026
Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL.

|Apr 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht

|Jan 09, 2026
Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.

Hyatt Balke-Want, Philipp Gödel, Christoph Schmid

|Oct 22, 2025
Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Giulia Magno, Kai Rejeski, Giulia Rappa

|Aug 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Florian Simon, Rudy Ligtvoet, Sandra Robrecht

|May 02, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.

Nadine Kutsch, Adam Giza, Sandra Robrecht

Pageof 3

Frequent Collaborators

2 joint publications

Moritz Fürstenau

2 joint publications

Arnon P Kater

2 joint publications

Florian Simon

2 joint publications

Philipp Bernhard Staber